Global Principles on Incentivizing Antibiotic R&D
The COVID-19 pandemic has made it very clear that the
world needs to be better prepared for global threats posed
by infectious diseases. Antimicrobial resistance (AMR), if left
unchecked, risks undermining the achievements of modern
medicine and taking us back to a time where a simple cut
could become lethal.
Now, more than ever, we need to accelerate the creation of
a vibrant and sustainable innovation ecosystem to support
R&D for new antibiotics and other antimicrobials addressing
pathogens prioritized by leading public health bodies.
We call on governments to deliver new economic incentives,
pragmatic antibiotic value assessments, and reimbursement
reforms to enable access, that are needed to meet the needs
of patients of today and tomorrow.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.